Background: Because of the overwhelming benefit of thrombectomy for highly selected trial patients with large vessel occlusion (LVO), some trial-ineligible patients are being treated in practice.
Objective: To determine the safety and efficacy of thrombectomy in DAWN/DEFUSE-3-ineligible patients.
Methods: Using a multicenter prospective observational study of consecutive patients with anterior circulation LVO who underwent late thrombectomy, we compared symptomatic intracerebral hemorrhage (sICH) and good outcome (90-d mRS 0-2) among DAWN/DEFUSE-3-ineligible patients to trial-eligible patients and to untreated DAWN/DEFUSE-3 controls.
Results: Ninety-eight patients had perfusion imaging and underwent thrombectomy >6 h; 46 (47%) were trial ineligible (41% M2 occlusions, 39% mild deficits, 28% ASPECTS <6). In multivariable regression, the odds of a good outcome (aOR 0.76, 95% CI 0.49-1.19) and sICH (aOR 3.33, 95% CI 0.42-26.12) were not different among trial-ineligible vs eligible patients. Patients with mild deficits were more likely to achieve a good outcome (aOR 3.62, 95% CI 1.48-8.86) and less sICH (0% vs 10%, P = .16), whereas patients with ASPECTS <6 had poorer outcomes (aOR 0.14, 95% CI 0.05-0.44) and more sICH (aOR 24, 95% CI 5.7-103). Compared to untreated DAWN/DEFUSE-3 controls, trial-ineligible patients had more sICH (13%BEST vs 3%DAWN [P = .02] vs 4%DEFUSE [P = .05]), but were more likely to achieve a good outcome at 90 d (36%BEST vs 13%DAWN [P < .01] vs 17%DEFUSE [P = .01]).
Conclusion: Thrombectomy is used in practice for some patients ineligible for the DAWN/DEFUSE-3 trials with potentially favorable outcomes. Additional trials are needed to confirm the safety and efficacy of thrombectomy in broader populations, such as large core infarction and M2 occlusions.
Keywords: Acute stroke; Computed tomography; Perfusion imaging; Thrombectomy.
Copyright © 2019 by the Congress of Neurological Surgeons.
Application of the DAWN clinical imaging mismatch and DEFUSE 3 selection criteria: benefit seems similar but restrictive volume cut-offs might omit potential responders.Eur J Neurol. 2018 Aug;25(8):1093-1099. doi: 10.1111/ene.13660. Epub 2018 May 10. Eur J Neurol. 2018. PMID: 29667266
DEFUSE 3 Non-DAWN Patients.Stroke. 2019 Mar;50(3):618-625. doi: 10.1161/STROKEAHA.118.023310. Stroke. 2019. PMID: 30727856 Free PMC article. Clinical Trial.
Thrombectomy 6-24 hours after stroke in trial ineligible patients.J Neurointerv Surg. 2018 Nov;10(11):1033-1037. doi: 10.1136/neurintsurg-2018-013915. Epub 2018 May 17. J Neurointerv Surg. 2018. PMID: 29773716 Clinical Trial.
Endovascular Thrombectomy for Acute Ischemic Stroke.Curr Cardiol Rep. 2019 Aug 30;21(10):112. doi: 10.1007/s11886-019-1217-6. Curr Cardiol Rep. 2019. PMID: 31471811 Review.
Indications for Mechanical Thrombectomy-Too Wide or Too Narrow?World Neurosurg. 2019 Jul;127:492-499. doi: 10.1016/j.wneu.2019.04.116. Epub 2019 Apr 19. World Neurosurg. 2019. PMID: 31009772 Review.